Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Adults in Tanzania living with HIV and taking tenofovir have a higher rate of chronic kidney disease vs. those without the ...

For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

In a remarkable display of market confidence, VATE stock has surged to a 52-week high, with shares trading at an impressive $13.31, representing a dramatic 309% increase from its 52-week low of $3.25.

Denmark: A recent study published in the Journal of Diabetes and its Complications has explored the role of kidney fat ...

The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...

CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...